In doing some research this weekend, I definitely sold too hastily.  While they don't have any major catalysts on the calendar for next few months, they are squarely focused on heart disease for their gene editing research - which is an enormous TAM (total addressable market).

Market cap not in line with that at around $1.8B, so will be buying my Bou back and holding.